Clinical trials: Disorders of Calcium and Bone Metabolism
Hemodyalysis, Kidney Tansplant
Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general…
- Conditions
- Hemodyalysis, Kidney Tansplant, Osteoporosis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT07141043
- Where
- Romania
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Hypophosphatemic Rickets
Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
Fibroblast growth factor 23 (FGF23) is the cornerstone of phosphate / calcium / vitamin D metabolism: it is synthesized mainly by osteocytes and acts as a Phosphating agent, inhibitor of dihydroxyvitamin D, and inhibitor of…
- Trial name
- HYPO-CLASTE (NCT04184661)
- Testing
- blood sample
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Hospices Civils de Lyon
Polyostotic Fibrous Dysplasia
Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
This study will investigate how a gene mutation (change in DNA) causes the abnormal bone in fibrous dysplasia-a condition in which areas of normal bone are replaced with a fibrous growth similar to a scar.
- Trial name
- NCT00001973
- Where
- United States
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Osteoporosis, Renal Osteodystrophy
The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
This is a Phase 2 Multi-Center Clinical Trial (safety and effectiveness trial) in 60 patients (40 denosumab; 20 placebo) who have had a kidney transplant for 12-months or longer with more than 30% of kidney function.
- Conditions
- Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
- Trial name
- ProliaKTx (NCT03960554)
- Testing
- Denosumab Inj 60 mg/ml
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Thomas Nickolas, MD MS
Restless Leg Disorder, Renal Disease Bone
Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
Restless leg syndrome (RLS) is sleep disorder characterized by an unpleasant feeling in the lower limbs, which can be accompanied by paresthesias, and need for urgent movement of the legs.
- Conditions
- Restless Leg Disorder, Renal Disease Bone, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- RLS (NCT03063190)
- Testing
- Vitamin D
- Where
- Brazil
- Sponsor
- University of Sao Paulo General Hospital
Hypophosphatasia (HPP)
Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP.
- Trial name
- NCT02104219
- Where
- 19 sites in United States, Australia and 6 more
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
X-Linked Hypophosphatemic Rickets
Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets FLAM-XLH
X-linked hypophosphataemia (XLH) is a rare genetic disorder associated with increased circulating levels of the hormone FGF23, most commonly through mutation of the PHEX gene.
- Trial name
- FLAM-XLH (NCT06248632)
- Testing
- Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Rickets, Osteomalacia
Maternal and Infant Vitamin Status During the First Nine Months of Infant Life
In this study the investigators wanted to assess vitamin D status and possible consequences of low plasma 25-hydroxyvitamin D levels in a population of healthy mothers and their infants, in the community of Aarhus, Denmark.
- Conditions
- Rickets, Osteomalacia, Osteoporosis
- Trial name
- NCT02548520
- Testing
- Blood and breastmilk samples
- Where
- Denmark
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
X-linked Hypophosphatemia
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
- Trial name
- NCT01340482
- Testing
- KRN23
- Where
- 6 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemic Rickets/Osteomalacia
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 administered subcutaneously once every 2 weeks in children with X-linked hypophosphatemic rickets/osteomalacia(XLH).
- Trial name
- NCT03233126
- Testing
- KRN23
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Osteoporosis, Osteopenia
Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women
Osteopenia and osteoporosis cause thinning of bone tissue and loss of bone density over time. The purpose of this study is to determine the safety and effectiveness of nitroglycerin ointment for the treatment of osteopenia in…
- Trial name
- NCT00043719
- Testing
- Nitroglycerin ointment, Calcium supplement with vitamin D
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Osteoporosis
Soluble Corn Fiber and Calcium Utilization in Adolescents
The purpose of this study was to determine the effect of soluble corn fiber on calcium absorption and retention and gut microflora in adolescent boys and girls.
- Trial name
- NCT01571440
- Testing
- No soluble corn fiber, 12 g soluble corn fiber
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue University
Hypophosphatasia (HPP)
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.
- Trial name
- NCT00744042
- Testing
- asfotase alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 11 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Osteoporosis
Effect of Sodium Intake on Calcium Retention in Girls
Optimal calcium retention is important for building bone mass within the genetic potential, a key to reducing risk of osteoporosis later in life. Calcium retention is high during the rapid growth period.
- Trial name
- NCT01564238
- Testing
- Low Na diet (1.3 g/d), High sodium diet (3.8 g/d)
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Purdue University
Osteoporosis
Effect of Calcium and Vitamin D on Bone Loss From the Hip
The primary aim of this study is to determine the effects of supplementation with both calcium and vitamin D on changes in bone density of the hip in men and women age 65 and older.
- Trial name
- NCT00357643
- Testing
- Calcium 500 mg/day and vitamin D 700 IU/day
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Tufts University
Hypocalcemia, Postoperative Parathormone
Early Prediction of Hypocalcemia After Thyroidectomy Using Postoperative Second Hour Parathormone
Hypocalcemia is the most frequent complication in thyroid surgeries. Diagnosing this complication earlier will reduce longer hospital stay and will lead to an earlier intervention.
- Trial name
- NCT03717116
- Testing
- parathormone level
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Istanbul University
X-linked Hypophosphatemia
Anti-FGF23 (Burosumab) in Adult Patients With XLH
X-linked hypophosphatemia (XLH) rare genetic disorder due by inactivating mutations in the PHEX gene leading to increased levels in FGF-23.
- Trial name
- BurGER (NCT04695860)
- Testing
- Burosumab
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Wuerzburg University Hospital
Osteoporosis
Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
This study will evaluate the safety, tolerability and exposure of SB-751689 when administered alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a PGP/CYP3A4 inhibitor that increases exposure…
- Trial name
- NCT00468689
- Testing
- SB-751689 oral tablets (100 and 400 ng), Ketoconazole (NIZORAL) oral tablets (200 mg)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
End Stage Kidney Disease (ESKD), Hemodialysis
Medium Cut-Off and High-Flux Membranes on Mineral and Bone Metabolism in Hemodialysis Patients
This study aims to compare the effects of medium cut-off (MCO) and high-flux hemodialysis membranes on mineral and bone metabolism biomarkers in patients receiving maintenance hemodialysis.
- Conditions
- End Stage Kidney Disease (ESKD), Hemodialysis, Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- MBD-HD (NCT07685223)
- Testing
- Medium Cut-Off Hemodialysis Membrane, High-Flux Hemodialysis Membrane
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Gazi University